Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.

Neurotherapeutics · 2018 · PMC5794691 · PMID 28924870

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

nearly significantp = 0.054so close (0.05 < p ≤ 0.1)

However, this difference was nearly significant for premature withdrawals due to cancer progression [2/27 (7.4%) vs 9/36 (25.0%); p = 0.054].

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.